Serna Bio is building the world’s first map of the druggable transcriptome, systematically opening up the universe of RNA biology to small molecule drug discovery. Using our Discovery Platform, we are tackling the classically intractable targets, with an initial focus on Oncology and Rare Disease. The current toolkit for developing drugs is focused almost entirely on protein targets. However, 85% of the approximate 3 billion base pairs in the human genome encodes for RNA but not protein. Our platform enables a novel approach to understand RNA structure, function and binding sites in order to develop a new class of drugs. Targeting RNA in this way enables us to explore therapeutics for the many diseases with no known treatments.


Operations

Serna Bio

Backed is a London-based VC fund, set up to do things differently.\r\n\r\nWe back unashamedly ambitious founders, building tech companies that give people greater freedom. \r\nWe invest at the seed stage in Europe and the US. \r\n\r\nWe’re a young team - our founders are our peers. \r\nWe roll up our sleeves - companies deserve more than just capital. \r\n\r\nOur platform helps founders hire talent, develop their brands, build communities and expand internationally.

Job Opportunities in the Backed Portfolio